StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
EIKO.BO$52.95+1.20%
Fair $52.95+0.0%

EIKO.BO

Eiko Lifesciences Ltd

Basic Materials / Specialty ChemicalsBSE

$52.95

+0.63 (+1.20%)

Fairly Valued+0.0%Fair Value $52.95Fund rank 24/100 · Data gapFallback financials|
SA 55/C
F-Score: 7/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-73.7M · quality 43.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 0/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

55/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is 3.7%, below the 5% threshold
Thesis & Journal · EIKO.BOLocal privado en este navegador · Eiko Lifesciences Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$767M

P/E

16.9x

↑

EV/EBITDA

15.2x

↑

ROE

3.7%

↑

Gross Margin

9.4%

↓

Debt/Equity

0.05

↓
52-Week Range$53
$46$66

TradingView lightweight chart

EIKO.BO price, volumen y niveles de valoración

Último $52.95Periodo +397.5%
Fair value: $52.95

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.3%

FCF CAGR

—

FCF margin

-20.4%

FCF / Net income

-3.50x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $360.3M · net income $21.1M · FCF $-73.7M

2022-FY → 2025-FY

Gross margin

9.4%+1.1% pts

Operating margin

3.0%-0.1% pts

Net margin

5.8%+3.1% pts

FCF margin

-20.4%+10.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$360.3M$360.3M$279.3M$183.2M$254.3M
Net Income$21.1M$21.1M$7.5M$7.7M$7.1M
EBITDA$39.5M$39.5M$17.9M$18.1M$18.7M
EPS1.621.620.730.790.78
Gross Margin9.4%9.4%8.2%9.2%8.3%
Operating Margin3.0%3.0%3.4%1.8%3.2%
Net Margin5.8%5.8%2.7%4.2%2.8%
Balance Sheet
Debt/Equity0.050.05—0.000.16
Current Ratio3.083.08———
Cash Flow
Free Cash Flow$-73.7M$-73.7M$-74.8M$40.0M$-78.8M
Returns
ROE3.7%3.7%1.5%2.6%2.5%
Valuation
P/E16.9216.9274.5994.0852.89
EV/EBITDA15.1715.1723.9439.8922.20
P/B1.221.221.112.471.30
Growth & Yield
Revenue Growth29.0%29.0%52.4%-28.0%—
EPS Growth121.9%121.9%-7.6%1.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

42.6%

muy exigente

EPS terminal req.

$4.70

Spread vs growth

79.3%

5Y implied EPS CAGR

28.5%

muy exigente

EPS terminal req.

$5.69

Spread vs growth

93.4%

10Y implied EPS CAGR

18.9%

exigente

EPS terminal req.

$9.16

Spread vs growth

103.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +3.4%

Total return

+3.4%

Start / end P/E

70.2x → 32.7x

EPS bridge

0.73 → 1.62

Residual

-65.1%

EPS growth+121.9%
Multiple rerating-53.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term-65.1%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.